Special Issue on Multifunctional Nanosystems: From Biomaterials to Theranostics; Guest Editor: Francois Berthiaume and Prabhas Moghe — Research PapersNo Access

LOW-DOSE RECOMBINANT VACCINE ANTIGEN DELIVERY BY ENGINEERED OUTER MEMBRANE VESICLES

JOSEPH ROSENTHAL

Department of Biomedical Engineering, Cornell University, 237 Tower Rd., Ithaca NY 14853, USA

Search for more papers by this author

TIFFANY LEUNG

Department of Biological and Environmental Engineering, Cornell University, Riley-Robb Hall, Ithaca, NY 14850, USA

Search for more papers by this author

MATTHEW DELISA

School of Chemical and Biomolecular Engineering, Cornell University, 254 Olin Hall, Ithaca, NY 14853, USA

Search for more papers by this author

, and

DAVID PUTNAM

Department of Biomedical Engineering, Cornell University, 237 Tower Rd., Ithaca, NY 14853, USA

School of Chemical and Biomolecular Engineering, Cornell University, 254 Olin Hall, Ithaca, NY 14853, USA

Search for more papers by this author

https://doi.org/10.1142/S1793984413420026Cited by:0 (Source: Crossref)

Abstract

The use of engineered antigen carriers to optimize the immune response to recombinant subunit vaccines has seen great advances in recent years. Optimization can take several forms, such as facilitating stimulation of certain immune cells or amplifying the adjuvancy effect of the vaccine formulation. In this paper, we applied dose/response analysis to demonstrate the ability of outer membrane vesicle (OMV) antigen carriers derived from engineered Escherichia coli to produce strong antigen-specific immune responses to a model antigen at a significantly decreased antigen load compared to an industry standard alum-based control. Inflammopathology and histological analysis of extended studies further supported a capacity to enhance immune cell recruitment locally at the injection site while decreasing inflammation and eliminating injection site scaring. The results indicate a strong potential for OMV-based vaccines as recombinant antigen delivery vehicles, affording strong immunogenicity at low doses with a broadly applicable platform for recombinant subunit antigen inclusion.

Keywords:

References

M. Singh , A. Chakrapani and D. O'Hagan , Expert Rev. Vaccines 6 , 797 ( 2007 ) . Crossref, Google Scholar
V. E. J. C. Schijns and W. G. J. Degen , Clin. Pharmacol. Ther. 82 , 750 ( 2007 ) . Crossref, Google Scholar
J. H. Wilson-Welder et al. , J. Pharm. Sci. 98 , 1278 ( 2009 ) . Crossref, Google Scholar
S. J. Thomas and T. P. Endy , Curr. Opin. Infect. Dis. 24 , 442 ( 2011 ) . Crossref, Google Scholar
D. T. O'Hagan and N. M. Valiante , Nat. Rev. Drug Discov. 2 , 727 ( 2003 ) . Crossref, Google Scholar
D. Putnam , Nat. Mater. 5 , 439 ( 2006 ) . Crossref, Google Scholar
C.-J. Huang , A. J. Lower and C. A. Batt , Appl. Microb. Biotechnol. 87 , 401 ( 2010 ) . Crossref, Google Scholar
L. Steeghs et al. , J. Endotoxin Res. 10 , 113 ( 2004 ) . Google Scholar
J.-Y. Kim et al. , J. Mole. Biol. 380 , 51 ( 2008 ) . Crossref, Google Scholar
D. J. Chen et al. , Proc. Nat. Acad. Sci. USA 107 , 3099 ( 2010 ) . Crossref, Google Scholar
T. N. Ellis and M. J. Kuehn , Microbiol. Mol. Biol. Rev. MMBR 74 , 81 ( 2010 ) . Crossref, Google Scholar
A. Kulp and M. J. Kuehn , Ann. Rev. Microbiol. 64 , 163 ( 2010 ) . Crossref, Google Scholar
M. J. Kuehn and N. C. Kesty , Genes Dev. 19 , 2645 ( 2005 ) . Crossref, Google Scholar
J. Holst et al. , Vaccine 27 , B3 ( 2009 ) . Crossref, Google Scholar
R. Gupta , Adv. Drug Deliv. Rev. 32 , 155 ( 1998 ) . Crossref, Google Scholar
M. L. Vidakovics et al. , PLoS Pathog. 6 , e1000724 ( 2010 ) . Crossref, Google Scholar
P. C. L. Beverley , Br. Med. Bull. 62 , 15 ( 2002 ) . Crossref, Google Scholar
T. R. Mosmann and R. L. Coffman , Annu. Rev. Immunol. 7 , 145 ( 1989 ) . Crossref, Google Scholar
A. Berger , BMJ 321 , 424 ( 2000 ) . Crossref, Google Scholar
M. A. Swartz , S. Hirouse and J. A. Hubbell , Sci. Trans. Med. 4 , 148rv9 ( 2012 ) . Crossref, Google Scholar
M. P. Girard , S. K. Osmanov and M. P. Kieny , Vaccine 24 , 4062 ( 2006 ) . Crossref, Google Scholar